Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma
Assessment of Diffusion-weighted Magnetic Resonance (MR) Imaging to Predict Chemotherapy Outcome in Liver Metastases and Hepatocellular Carcinoma (HCC)
Sponsor: Azienda Ospedaliera Niguarda Cà Granda
A observational or N/A phase clinical study on Hepatocarcinoma and Liver Metastases, this trial is completed. The trial is conducted by Azienda Ospedaliera Niguarda Cà Granda and has accumulated 8 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Mar 2022 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Mar 2022 [monthly]
Completed
-
May 2020 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Jun 2018 — May 2020 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Azienda Ospedaliera Niguarda Cà Granda
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- Santa Maria delle Grazie Hospital
- Società Italiana Radiologia Medica SIRM
- Stefano Colagrande
- Treviso cà Foncello Hospital
- University of Rome Tor Vergata
- University of Trieste
For direct contact, visit the study record on ClinicalTrials.gov .